Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $63.67 Consensus PT from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $63.67.

TARS has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Barclays reduced their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Finally, Guggenheim reiterated a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $47.15 on Friday. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.28. The business’s fifty day moving average price is $49.60 and its two-hundred day moving average price is $44.29. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market cap of $1.81 billion, a PE ratio of -12.38 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. On average, analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP lifted its stake in shares of Tarsus Pharmaceuticals by 3.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,531,896 shares of the company’s stock worth $140,191,000 after acquiring an additional 91,451 shares in the last quarter. Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after buying an additional 321,552 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company’s stock valued at $117,117,000 after purchasing an additional 17,839 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $105,714,000. Finally, Lord Abbett & CO. LLC grew its holdings in shares of Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock valued at $70,873,000 after purchasing an additional 685,111 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.